Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4971350 | 0.87 | NPY5R (0.39) | NOS3NOS1 | |
| SCHEMBL4461347 | 0.85 | DPP4 (0.40) | NOS3NOS1 | |
| SCHEMBL11515949 | 0.79 | POLB (0.44) | NOS3NOS1 | |
| SCHEMBL4605352 | 0.79 | POLB (0.44) | NOS3NOS1 | |
| SCHEMBL4480479 | 0.78 | KDM5A (0.34) | — | |
| SCHEMBL994623 | 0.76 | HTR2C (0.40) | MAPK1NOS3NOS1 | |
| SCHEMBL20465779 | 0.76 | CHRM2 (0.41) | MAPK1 | |
| SCHEMBL4475218 | 0.74 | F10 (0.35) | — | |
| SCHEMBL337152 | 0.72 | AKR1C3 (0.32) | — | |
| SCHEMBL17185334 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-15 | — | — | US | claimed |
| EP-1991540-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-15 | — | — | US | disclosed |
| WO-2007098214-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | PDE7A, PDE10A, PDE7B | MAPK1 1811/4885NOS3 495/4885NOS1 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.